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Statement of translational relevance:  
 
Tumors of the same type can show markedly different responses to the same 
treatment. The development of new treatments and their deployment in the clinic 
would benefit, therefore, from the introduction of imaging methods that allow an early 
assessment of treatment response in individual patients, allowing rapid selection of 
the most effective treatment for a specific patient. Multispectral optoacoustic 
tomography (MSOT) is a clinically applicable, real-time imaging modality that can 
generate relatively high-resolution cross-sectional images at depth. We show here 
that when used with a near infra-red (NIR) fluorophore-labelled probe that binds to 
apoptotic and necrotic cells MSOT can be used to image tumor cell death within an 
entire tumor volume. The technique can be used to characterize the heterogeneous 
response of a tumor to treatment and to determine the most effective therapy at an 
early stage following the start of treatment.  
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Abstract 
Purpose:  The development of new treatments and their deployment in the clinic 
may be assisted by imaging methods that allow an early assessment of treatment 
response in individual patients. The C2A domain of Synaptotagmin-I (C2Am), which 
binds to the phosphatidylserine (PS) exposed by apoptotic and necrotic cells, has 
been developed as an imaging probe for detecting cell death. Multispectral 
optoacoustic tomography (MSOT) is a real-time and clinically applicable imaging 
modality that was used here with a near infrared (NIR) fluorophore-labeled C2Am to 
image tumor cell death in mice treated with a TNF-related apoptosis-inducing ligand 
receptor 2 (TRAILR2) agonist and with 5-fluorouracil (5-FU).  
Experimental design: C2Am was labeled with a near infrared (NIR) fluorophore and 
injected intravenously into mice bearing human colorectal TRAIL-sensitive Colo205 
and TRAIL-resistant HT-29 xenografts that had been treated with a potent agonist of 
TRAILR2 and in Colo205 tumors treated with 5-FU. 
Results: Three dimensional MSOT images of probe distribution showed 
development of tumor contrast within 3 h of probe administration and a signal-to-
background ratio in regions containing dead cells of >10 after 24 h.  A site-directed 
mutant of C2Am that is inactive in PS binding showed negligible binding. Tumor 
retention of the active probe was strongly correlated (R2=0.97, P value<0.01) with a 
marker of apoptotic cell death measured in histological sections obtained post 
mortem.  
Conclusions: The rapid development of relatively high levels of contrast suggests 
that NIR fluorophore-labeled C2Am could be a useful optoacoustic imaging probe for 
detecting early therapy-induced tumor cell death in the clinic.  
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Introduction 
DNA sequencing of tumor biopsies or of circulating tumor DNA (ctDNA), and 
detection of early treatment response through increases in the levels of ctDNA, are 
expected to play an increasingly important role in selecting treatment for individual 
patients (1,2). However, tumor heterogeneity remains an obstacle for both 
approaches.  Biopsies may not detect all clones present within a tumor and the 
presence of residual treatment-resistant clones may not be reflected in the levels of 
ctDNA released following treatment. Imaging methods that can detect treatment 
response throughout the entire tumor volume are likely, therefore, to play an 
important role in treatment selection (3). 
 Tumor cell death represents a generic downstream marker of treatment response 
and consequently there has been considerable interest in developing imaging 
methods and agents to detect tumor cell death in vivo (4). We have developed a 
targeted imaging agent based on the C2A domain of Synaptotagmin-I, which binds 
with nanomolar affinity to the phosphatidylserine (PS) exposed on the plasma 
membrane of dying cells (5).  The protein was used initially as a glutathione-S-
transferase (GST) fusion protein, where imaging labels were attached to lysine 
residues, and used to detect tumor cell death using magnetic resonance and 
radionuclide imaging (6-9).  Subsequently, we developed a much smaller derivative 
of C2A (16 kDa) based on the isolated C2A domain (C2Am), in which we introduced 
a unique cysteine residue distant from the PS binding site. This allowed site-specific 
attachment of imaging labels, without affecting binding affinity, and the production of 
a chemically homogeneous preparation of the agent.  The smaller size allows for 
relatively rapid renal clearance, the production of a homogeneous agent rules out the 
possibility of labeled material that does not bind PS, or shows only weak binding, 
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and the removal of the GST tag, by lowering potential immunogenicity, increases 
clinical translatability.  C2Am, when labeled with a fluorophore, showed better 
specificity for binding to dead cells than a similarly labeled Annexin V derivative (5). 
Fluorescently labeled Annexin V is widely used to detect cell death in vitro and, in 
radionuclide-labeled form, has also translated to the clinic. However, clinical use of 
this agent was limited by poor specificity and relatively high levels of background 
binding (10). 
 The relatively high sensitivity, minimal tissue absorption and low cost of near 
infrared (NIR) fluorescence imaging have made this a widely used technique for non-
invasive imaging in small animals (11) and increasingly in the clinic (12).  However, 
image depth and resolution are limited by scattering, with depths of 1-2 cm and 
resolutions of 1-2 mm (13). Optoacoustic imaging can give three-dimensional (3D) 
tomographic images and can generate relatively high-resolution images at depths of 
a few centimeters.  In this technique NIR radiation is administered in the form of 
nanosecond laser pulses.  Absorption by chromophores in endogenous materials, 
such as oxy- and deoxyhemoglobin and melanin, or in contrast agents introduced 
exogenously, results in thermoelastic expansion and the production of a pressure 
wave that can be detected non-invasively using ultrasound transducers. Since 
pressure waves are relatively low frequency they are scattered much less than light 
or NIR radiation and so can be used to generate much higher resolution images.  
Detectors operating around 5 MHz enable penetration depths of several centimeters 
with resolutions between 100–400 μm, while detectors operating in the 10–100 MHz 
frequency range penetrate 1–10 mm with resolutions in the tens of micrometres (14). 
In multispectral optoacoustic tomography (MSOT) measurements are made at 
several NIR wavelengths in less than a second, which enables real-time imaging of 
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individual chromophores within entire tumor volumes.  With the introduction of a 
hand held device, bed-fitted devices and the development of real-time three-
dimensional optoacoustic tomography (14,15), clinical applications of MSOT have 
started to emerge, including screening of dense breasts for the presence of tumors 
(16,17), monitoring the metastatic status of sentinel lymph nodes in melanoma 
patients (18) and assessment of inflammatory disease (19). 
 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 
(TRAILR2) is a death receptor upregulated in a wide range of human tumors (20-22), 
which upon ligation triggers apoptosis through activation of a caspase cascade. 
MEDI3039 is a multivalent TRAILR2 agonist that can induce cell death in tumor cells 
at picomolar concentrations (23,24). 
 We describe here in vivo imaging measurements of early tumor responses to 
MEDI3039, and also 5-FU, using NIR fluorophore-labeled C2Am, using both optical 
imaging and MSOT. Non-specific probe binding was assessed using a site-directed 
mutant that is inactive in PS binding (iC2Am) (25).  The MSOT signal from C2Am 
was increased significantly in MEDI3039 and 5-FU-treated Colo205 tumors as early 
as 3 h post probe injection, whereas there was negligible retention of iC2Am in 
MEDI3039-treated tumors. Subsequent histological analyses showed that the C2Am 
signal observed in vivo was strongly correlated with immunostaining of dead cells in 
tumor sections. 
 
Materials and methods 
Cell culture. Human colorectal adenocarcinoma Colo205 cells were cultured in 
RPMI-1640 medium (Life Technologies Ltd., Paisley, UK) and HT-29 in McCoy's 5A 
(Modified), GlutaMAX™ medium (Life Technologies Ltd.). Both media were 
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supplemented with 10% fetal bovine serum (FBS; Lonza, Basel Switzerland). The 
cell lines were purchased from ATCC and both tested negative for mycoplasma by a 
RNA capture ELISA-based method. Cell lines were cultured in a humidified incubator 
at 37° C and 5% CO2.  The sensitivities of Colo205 and HT-29 cells to MEDI3039 
treatment were assessed by measuring cell viability at 22 h after drug treatment.  
Briefly, the cells were collected after drug treatment and resuspended to a density of 
1 x 106 cells/mL in medium. Ten μL cell samples were mixed with ten μL Trypan blue 
dye solution and cell viability assessed using a cell viability analyzer (LunaTM 
Automated Cell Counter, Logos Biosystems, France).  Cell viability was also 
assessed in Colo-Dual cells, which expressed luciferase (see below), by the addition 
of D-luciferin solution (25 μg/μl; SynChem Inc., Elk Grove Village, IL) to a 96-well 
with 5,000 cells per well. Bioluminescence imaging (BLI) measurements were 
performed 10 minutes later using an IVIS 200 series camera (PerkinElmer, Waltham, 
MA) with an F-stop of 1 and open filter.  All the samples were prepared in triplicate. 
 
Generation of Colo-Dual cell lines.  Cells were transduced with a lentiviral vector 
in which the EF1 promoter drives transcription of the red fluorescent protein, 
mStrawberry, and firefly luciferase (26). The mStrawberry coding sequence is 
separated from the luciferase coding sequences by an E2A sequence (EF1-L-S), 
which results in similar levels of expression of mStrawberry and luciferase. 
Lentiviruses were produced by co-transfecting HEK 293T cells with the EF1-L-
S plasmid and packaging plasmids. Supernatants containing lentiviruses were 
collected 72 h after transfection, mixed with polybrene (8 μg/ml) and used to infect 
Colo205 cells. After 72 h cells displaying similar levels of red fluorescence were 
sorted, using a BD FACSAria cell sorter (BD Biosciences, Rockville, MD). 
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Conjugates of C2Am and iC2Am. Conjugates of C2Am and iC2Am with VivoTag®-
S 750-MAL (excitation wavelength: 750±5nm; emission wavelength: 775±5nm, 
PerkinElmer, Waltham, MA) and iC2Am with IRDye® 680RD (excitation wavelength: 
672nm; emission wavelength: 694nm, LI-COR Biosciences, Lincoln, NE) were 
prepared as described previously (5).  This conjugation protocol has been shown 
previously to produce conjugates of C2Am and iC2Am that were fully modified, 
yielding a single molecular species on electrospray ionization mass spectrometry 
(5,25). The optical absorption spectrum of 1 μM C2Am-750 in phosphate-buffered 
saline (PBS) was measured using a PHERAStar FS spectrometer (BMG LABTECH, 
Bucks, UK).  
 
Flow Cytometry. Following treatment with 1 pM MEDI3039 for 22 h, Colo205 and 
HT-29 cells were resuspended in 100 μL of pre-cooled HEPES-buffered saline (10 
mM HEPES, 150 mM NaCl, 2 mM CaCl2, pH 7.4) with 1% FBS. The cell 
suspensions were incubated with a 1:1 mixture of C2Am-750 and iC2Am-680 at a 
concentration of 300 nM, and SYTOX Green (Invitrogen; 50 nM) for 20 min at 37 °C, 
and then washed twice and kept briefly on ice before being analyzed using an LSR II 
cytometer (BD Biosciences).  For blocking experiments, the cell suspensions were 
first incubated with an excess of unlabeled C2Am (30 μM) for 30 min before the 
addition of labeled C2Am and iC2Am.  Data were analyzed using FlowJo software. 
MEDI3039 was supplied as a stock solution of 10 mg/mL in PBS. 
 
Confocal microscopy. Colo-Dual cells were cultured in a glass bottomed culture 
dish (MatTek Crop., Ashland, MA) until 80% confluent. Cell death was induced by 
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incubation of the cells with 10 pM MEDI3039 for 5 h. The cells were then incubated 
in 200 μL of RPMI-1640 medium with a 1:1 mixture of C2Am-750 and iC2Am-680 at 
a concentration of 500 nM for 20 min at 37°C. The cells were then washed twice 
gently with phenol red-free RPMI-1640 medium (Life Technologies Ltd.) and imaged 
using a Leica TCS SP5 confocal microscope (Leica Microsystems Ltd, Milton 
Keynes, UK). Intrinsic NADH autofluorescence was measured using an Argon-UV 
laser, with an excitation wavelength range of 340±30 nm, and an emission bandpass 
filter of 411 - 491 nm.  mStrawberry fluorescence was measured using a HeNe 543 
laser, with an excitation peak at 574 nm, and an emission bandpass filter of 560 - 
620 nm.  
 
Animal Experiments. Female nude mice at ~20 g (BALB/c nu/nu, ~8 weeks old) 
were acquired from Charles River Laboratories. All surgical and imaging procedures 
were performed under isoflurane gas anesthesia (3% for induction, 2% for 
maintenance). Animals were sacrificed by cervical dislocation at the endpoint. All 
animal experiments were carried out under the authority of project and personal 
licenses issued by the United Kingdom Home Office under the United Kingdom 
Animals (Scientific Procedures) Act, 1986, and had been reviewed by the Cancer 
Research UK, Cambridge Institute Animal Welfare and Ethical Review Body. 
 
Imaging Procedures.  For fluorescence imaging two groups of mice (n = 5 each) 
were implanted with 5 x 106 Colo205 cells. Two weeks later one group received a 
single intravenous (i.v.) injection of 0.4 mg/kg MED3039. Another group, which 
served as an untreated control, were injected with solvent vehicle (PBS). After 16 h 
the mice were injected i.v. with a mixture of 0.1 µmole/kg C2Am-750 and 0.1 
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µmole/kg iC2Am-680 (0.2 mL of a solution containing 10 µM of each probe) and 
fluorescence images were acquired 0.5 and 3 h later using an IVIS 200 series 
camera with an F-stop of 2.  The wavelengths used for fluorescence imaging were 
dictated by the available filter sets on the IVIS camera.  (i)C2Am-750 was imaged 
with an excitation bandpass filter of 705 - 780 nm and an emission bandpass filter of 
810-885 nm.  iC2Am - 680 was imaged with an excitation bandpass filter of 615 - 
665 nm and an emission bandpass filter of 695 - 770 nm. A correction factor of 3.98 
was applied to signals from C2Am-750, when comparing them with iC2Am-680, due 
to the differences in fluorescence emission from the two fluorophores. The correction 
factor was calculated by measuring the fluorescence intensities, using the IVIS 
camera, of iC2Am-680 and C2Am-750 diluted to a concentration of 2 µM in PBS 
containing 1% FBS. The average radiant efficiency of iC2Am-680 was then divided 
by the average radiant efficiency of C2Am-750 to obtain a factor that could be used 
to correct for the more intense fluorescence of the 680 dye. Similar fluorescence 
measurements were made in groups of mice (n = 3) implanted with 5 x 106 HT-29 
cells. Regions of interest were analyzed using Living Image software (PerkinElmer). 
 
For BLI, two groups of mice (n = 5 each) were implanted with 5 x 106 Colo-Dual cells.  
After 11 days images were acquired from both groups of animals 10 min after 
intraperitoneal injection (i.p.) of D-luciferin (150 mg/kg) using the IVIS camera with 
an F-stop of 1 and an open filter.  The treated group was then injected with a single 
dose of 0.4mg/kg MEDI3039. Untreated animals (n=5) were injected with drug 
vehicle (PBS) and images were acquired two to three times per week from both 
groups.  
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For optoacoustic imaging, a MultiSpectral Optoacoustic Tomography (MSOT) 
inVision 256-TF small animal imaging system (iThera Medical, Munich, Germany) 
was used. Briefly, a tunable optical parametric oscillator (OPO) pumped by an 
Nd:YAG laser provides excitation pulses with a duration of 9 ns at wavelengths from 
660 nm to 1300 nm at a repetition rate of 10 Hz with a wavelength tuning speed of 
10 ms and a peak pulse energy of 90 mJ at 720 nm. Ten arms of a fiber bundle 
provide uniform illumination of a ring-shaped light strip of approximately 8 mm width. 
For ultrasound detection, 256 toroidally focused ultrasound transducers, with a 
center frequency of 5 MHz (60% bandwidth) and organized in a concave array of 
270 degree angular coverage and a radius of curvature of 4 cm, are used (27).  Two 
groups of mice (n=5 each) were implanted with 5 x 106 Colo205 cells and two weeks 
later received a single dose of 0.4 mg/kg MED3039. After 4 h, the mice were injected 
with either 0.2 µmole/kg of C2Am-750 or iC2Am-750 and imaged. Another group 
(n=3), that were not treated with MEDI3039, were injected with 0.2 µmole/kg of 
C2Am-750.  For imaging, animals were anesthetized and placed on a heated pad 
before transferring into a custom-made cling film holder (iThera Medical). A small 
amount of distilled water was placed between the skin of the mouse and the layer of 
cling film for ultrasound coupling. The holder was placed in the MSOT scanner in a 
water bath maintained at a temperature of 36°C. MSOT measurements were 
performed before and at 3, 5, 7 and 24 h after probe injection, according to a 
protocol described previously (28). Cross-sectional multispectral image datasets 
were acquired at different wavelengths in the NIR window (660, 665, 670, 680, 690, 
700, 710, 720, 730, 740, 750, 755, 760, 770, 780, 800, 825, 850 and 900 nm) 
through the entire tumor region in 0.5 mm steps in the z-direction and at a single 
position where the kidneys were located. Scans at each illumination wavelength took 
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100 ms to acquire, and 10 averages were used to produce a final image, amounting 
to 20 s acquisition time per slice. Images were reconstructed using a model-based 
reconstruction algorithm, after which linear spectral unmixing was applied to each set 
of multi-wavelength images to resolve the biodistribution of the different tissue 
chromophores i.e. (i)C2Am-750, oxygenated and deoxygenated hemoglobin. Data 
were processed and quantified using the ViewMSOT software (iThera Medical). 
Volumetric quantification was done by comparing the signal-to-background ratio after 
drawing 3D reconstructed volumes of interest (VOIs) in the tumor area. Briefly, a 
signal-to-background ratio was calculated from the mean pixel intensity (MPI) of a 
VOI, drawn in an area where there was maximum signal, divided by the MPI of an 
adjacent size-matched VOI with low signal intensity. The volume percentage of 
tumor bound by C2Am-750 was taken as the volume with C2Am-750 signal above a 
threshold value (VT), where this was defined as the mean intensity of the 
background signal in the tumor volume before probe injection, divided by the total 
tumor volume (V).  This was compared with CC3 staining, where this was 
determined in tumor sections taken every 2 – 3 mm through the tumor volume.  
Corresponding fluorescence imaging measurements were made using an IVIS 
camera immediately after the MSOT measurements. 
 
Similar fluorescence and MSOT measurements were also made in Colo205 tumor-
bearing animals treated with 5-fluorouracil (5-FU).   Mice (n = 5) were implanted with 
5 x 106 Colo205 cells and then two weeks later fluorescence and MSOT 
measurements were performed before and 3 h after i.v. injection of 0.2 µmole/kg of 
C2Am-750.  Twenty four hours later the animals received a single intraperitoneal 
injection (250 mg/kg) of 5-FU and then 24 h after drug treatment the fluorescence 
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and MSOT measurements were repeated. The mean MSOT voxel intensity in the 
tumor area was compared before and after 5-FU treatment. For the biodistribution 
study the tumors and major organs, including kidney, spleen, heart, lung, liver, 
muscle and blood were excised immediately after completion of the in vivo imaging, 
weighed and then their fluorescence imaged using the IVIS-200 camera. 
 
Histopathology. Tumors were fixed in 4% formaldehyde and embedded in paraffin. 
Five µm sections were cut and imaged using the 700 nm and 800 nm channels of an 
Odyssey Infrared Imaging scanner (LI-COR). Images were generated at a resolution 
of 21 μm using two lasers, one emitting at 685 nm and the other at 785 nm. 
Consecutive sections were stained for cleaved caspase-3 (CC3), where a rabbit 
monoclonal anti-CC3 antibody (Cell Signaling Technology Inc,Danvers, MA) and a 
donkey anti-rabbit secondary biotinylated antibody (Jackson ImmunoResearch 
Laboratories. West Grove, PA) were used in a Polymer Refine Kit on an automated 
Bond platform (Leica Biosystems Ltd, Newcastle, UK); or they were stained using 
TdT-mediated dUTP Nick-End Labeling (TUNEL) using a DeadEnd Colorimetric 
system kit (Promega Benelux BV, Leiden, The Netherlands). Stained sections were 
scanned on an Aperio AT2 (Leica Biosystems) at x20 magnification, with a resolution 
of 0.5 μm per pixel.  All annotations were performed with ImageScope (Leica 
Biosystems) and the stained surface area was quantified using the algorithm 
‘Positive Pixel Count v9’ in Imagescope.  
 
Statistical analysis. Statistical analyses were performed in GraphPad Prism 
(GraphPad Software, La Jolla, CA). Data are shown as mean ± standard deviation, 
unless stated otherwise. A two-tailed Student T-test was used for pairwise 
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comparisons. Pearson’s r test was used to assess the significance of the correlation 
between CC3 staining and tumor binding of C2Am-750. P values of <0.05 were 
considered significant. 
 
Results 
HT-29 cells were largely resistant to MEDI3039, showing minimal loss of viability up 
to 10 pM drug concentration and only ~25% loss at much higher drug concentrations, 
whereas Colo205 cells showed ~50% loss of viability at low drug concentrations 
(EC50 1.3 pM) and complete loss of viability at higher drug concentrations (Figure 
1A).  This loss of viability, measured by Trypan blue dye exclusion, was mirrored in 
Colo-Dual cells by loss of bioluminescence (Figure 1B&C). Colo-Dual cells were 
transduced with a lentiviral vector to express firefly luciferase and the red fluorescent 
protein, mStrawberry.  The bioluminescence signal from these cells is indicative of 
intracellular ATP concentration.  Binding of C2Am labeled with a fluorescent dye 
excited at 750 nm (C2Am-750) and a site-directed mutant inactive in PS binding 
labeled with a fluorescent dye excited at 672nm (iC2Am-680) to MEDI3039-treated 
cells was characterized using confocal microscopy (Figure 2A) and flow cytometry 
(Figure 2B). The specificity of C2Am-750 for PS binding was confirmed by a blocking 
study with unlabeled C2Am (Supplementary Figure 1). Confocal microscopy 
measurements with Colo205-Dual cells treated with MEDI3039, showed that when 
compared to untreated cells there were relatively low levels of both NADH (intrinsic 
autofluorescence) and mStrawberry fluorescence, indicating cell death. These cells 
showed binding of C2Am-750 to the plasma membrane but negligible binding of 
iC2Am-680.  There was negligible binding of C2Am-750 to untreated cells (Figure 
2A). Flow cytometry of MEDI3039-treated TRAIL-sensitive Colo205 cells, but not 
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TRAIL-resistant HT-29 cells, showed increased binding of C2Am-750, which was 
correlated with a decrease in NADH autofluorescence and an increase in binding of 
a cell necrosis marker, Sytox Green (Figure 2B). iC2Am-680 showed negligible 
binding to either cell line, regardless of drug treatment. 
 
Next, we investigated the capability of C2Am-750 to detect tumor cell death in vivo, 
in Colo205 and HT-29 xenografts in BALB/c nu/nu mice. Three hours after probe 
injection, there was a significant increase in C2Am-750 retention in treated as 
compared to untreated Colo205 tumors, which was observed both in fluorescence 
measurements made in vivo (5.97-fold, P < 0.001) and on excised tumors ex vivo 
(4.1-fold, P value < 0.001) (Figure 3). Compared to C2Am-750, the retention of 
iC2Am-680 was significantly lower in both treated (P <0.001) and untreated (P 
<0.001) tumors.  These results were similar to those obtained previously with 5-
fluorouracil (5-FU)-treated Colo205 tumors (250 mg/kg of body weight; injected 
intraperitoneally), in which C2Am and iC2Am, both labeled with AlexaFluor™-750 
C5-maleimide, were injected separately (25).  There was no significant difference in 
C2Am-750 retention in treated and untreated HT-29 xenografts, which was 
comparable to the retention observed in untreated Colo205 tumors (Supplementary 
Figure 2).  iC2Am-680 retention was much lower in both groups. Fluorescence 
images of Colo205 tumor sections showed strong fluorescence signals from C2Am-
750 (green) that co-localized with regions stained with TUNEL (a marker of necrotic 
cell death) and cleaved caspase 3 (CC3, a marker of apoptotic cell death).  There 
was negligible signal from iC2Am-680 (blue), confirming the specificity of C2Am-750 
for binding to dead and dying cells (Figure 3B). Measurements of bioluminescence 
from Colo-Dual tumors showed that at this single dose of MEDI3039 (0.4 mg/kg) 
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there was a complete loss of signal within 24 h of drug treatment, which was 
maintained for up to 45 days after treatment (Figure 4A). The rapid loss of 
bioluminescence in treated tumors, presumably due to loss of ATP (Figure 4B), 
preceded decreases in tumor volume, which started one week after treatment. 
 
Next, we used MSOT to image retention of C2Am-750 and iC2Am-750 in MEDI3039-
treated Colo205 tumors. The system used here had a spatial resolution of ~150 µm 
at a penetration depth of 3 cm. Spectral unmixing was used to generate images of 
C2Am-750, iC2Am-750 and intrinsic tissue chromophores (deoxygenated and 
oxygenated hemoglobin) throughout the entire tumor volume. Representative MSOT 
images show that there was some retention of C2Am-750 in untreated tumors 
(Figure 5A). However, signal from C2Am-750 was increased markedly at 7 h after 
drug treatment and 3 h after probe injection. Maximal signal from C2Am-750 
appeared in the center of the treated tumors (Figure 5B), whereas there was 
negligible retention of iC2Am-750 (Figure 5C). Signal from kidney cortex confirmed 
that similar concentrations of C2Am-750 and iC2Am-750 had been injected in these 
animals. Axial, coronal and sagittal views showed that C2Am-750 was distributed 
throughout the entire tumor volume (Figure 5D).  Images reconstructed in three 
dimensions are shown in Figure 5E (video representations of these images are in 
supplementary data). An MSOT absorption spectrum from a region of high signal 
intensity at the center of a MEDI3039-treated tumor obtained 3 h after injection of 
C2Am-750 was similar to the optical absorption spectrum of C2Am-750 measured in 
vitro (Supplementary Figure 3), demonstrating that the MSOT signal observed in vivo 
arose predominantly from C2Am-750. 
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Dynamic MSOT measurements with C2Am-750 and iC2Am-750 in MEDI3039-
treated Colo205 tumors and parallel fluorescence images acquired from the same 
animals are shown in Figure 6. Both the MSOT (Figure 6A) and fluorescence images 
(Figure 6B) showed tumor retention of C2Am-750 for up to 24 h following probe 
injection, whereas there were only very low levels of iC2Am-750 in the tumor at 3 h 
and this had cleared by 24 h. At 24 h, the tumor signal-to-background ratio in 
animals injected with C2Am-750, in regions where there were high levels of C2Am-
750 binding, increased from 1.3 ± 0.5 prior to probe injection to 15.0 ± 4.0 following 
probe injection (ratio ± S.E.M., n = 5), whereas this ratio did not change in animals 
injected with iC2Am-750 (Figure 6C). The average volume occupied by bound C2Am 
in drug-treated tumors at 24 h post probe injection was correlated with CC3 staining 
of tumor sections obtained post mortem, where the tumors were excised immediately 
following imaging (R2=0.97, P value<0.01) (Figure 6D). Similar fluorescence signal 
intensities for C2Am-750 and iC2Am-750 were observed in the kidneys of these 
animals, confirming again that similar concentrations of the two probes had been 
injected. 
 
We have shown previously that fluorescently labeled C2Am can detect cell death in 
EL4 murine lymphoma cells treated with etoposide and MDA-MB-231 human breast 
cancer cells treated with doxorubicin (5) and that C2Am labeled with fluorescent and 
radionuclide labels can detect cell death in etoposide-treated EL4 tumors, 
cyclophosphamide-treated Eμ-myc tumors and Colo205 tumors treated with 5-FU 
(25).  Results of MSOT experiments with C2Am-750 in 5-FU-treated Colo-205 
tumors are shown in Supplementary Figure 4.   There was a significant increase in 
the MSOT signal from C2Am-750 at 24 h after 5-FU treatment and 3 h after probe 
 18 
injection.  A biodistribution study based on C2Am-750 fluorescence showed a 
significant increase in C2Am-750 retention in excised tumors compared to that in 
blood (4.05-fold, P < 0.001). Biodistribution data for fluorophore-labeled (i)C2Am-750 
has been reported previously, where we showed that the biodistribution profiles were 
similar to those of 99mTc- and 111In-labeled C2Am (25).    
 
Discussion 
Cell death, whether by apoptosis or necrosis, has attracted considerable attention as 
an imaging target since it is a generic marker for the presence of disease and 
additionally, in the case of cancer, a marker of response to treatment (4,29).  A 
number of cell death imaging agents have been developed, with some interacting 
with intracellular targets, such as CC3 (30), cytosolic proteins (31,32) and the 
mitochondrial membrane potential (33); or with extracellular targets, including 
exposed extracellular DNA (34), histones (35) and plasma membrane phospholipids 
(6,36). Plasma membrane phospholipids, such as PS and phosphatidylethanolamine 
(PE), which are normally present on the inner leaflet of the plasma membrane bilayer, 
are exposed on the surface of apoptotic cells and in necrotic cells by 
permeabilization of the plasma membrane to the imaging agent (37,38).  These 
phospholipids are an attractive target since in necrotic cells their exposure is 
persistent, which makes timing of imaging after cell death less critical, and they are 
abundant and therefore potentially capable of giving high signal-to-noise when 
bound by the imaging probe (7,39). In a previous study, titration of isolated apoptotic 
cells with fluorescently labeled C2Am gave an exposed PS concentration of 100 – 
300 pmol/106 cells (5), which assuming a tumor cell density in vivo of ~108 cells/ml, 
corresponds to a PS concentration in apoptotic tumor tissue of 10 – 30 μM. This 
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concentration is considerably in excess of the estimated minimum MSOT-detectable 
dye concentration in mouse tissue of 0.5 – 2 μM (14). 
 
We have shown previously that C2A, when conjugated to labels detectable by 
magnetic resonance (6,9), radionuclide and fluorescence imaging (25), is capable of 
detecting tumor cell death in vivo by binding to exposed PS.  We have also shown 
that C2Am is more specific than Annexin V in detecting cell death, which also binds 
PS, since C2Am shows less binding to viable cells (5).  The specificity of C2Am for 
detecting cell death was confirmed here by fluorescence measurements performed 
with C2Am and iC2Am in vitro and in vivo using MEDI3039-sensitive (Colo205) and 
resistant (HT-29) cell lines. Flow cytometry showed negligible binding of iC2Am and 
increased binding of C2Am to drug treated Colo205 cells but not to HT-29 cells.  
These findings were confirmed in implanted tumors in vivo and ex vivo by planar 
fluorescence imaging.  Histological analysis of Colo205 tumor sections confirmed 
binding of C2Am-750 to apoptotic and necrotic cells. 
 
Several targeted contrast agents for optoacoustic imaging of tumors have been 
developed in recent years (14,40,41), including dye-conjugated EGF, which was 
used to image EGF receptor expression in an orthotropic pancreatic cancer model 
(42), and a dye-conjugated cyclic peptide, which was used to image expression of 
the integrin, αvβ3, in an orthotropic brain tumor model (43). There has been a recent 
preliminary study in which a PS-binding antibody was used to image cell death in an 
implanted human breast cancer model in nude mice (44). However, the injected 
concentration was not specified nor was the statistical significance of the increase in 
signal intensity, which only appeared to be increased significantly at a time when the 
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tumor was already shrinking. Moreover, there was no histological validation, or 
control measurements with a non-PS binding IgG.  
 
We have shown here that MSOT measurements with a NIR fluorophore-labeled PS 
binding protein, C2Am-750, can be used to create 3D images of tumor cell death in 
human colorectal xenografts treated with a novel TRAILR2 agonist, MEDI3039. The 
C2Am-750 signal in treated Colo205 tumors increased as early as 3 h post probe 
injection, and at 24 h the signal-to-background ratio, for those regions showing the 
greatest binding, was >10. There was negligible retention of a site-directed mutant of 
C2Am, which is inactive in PS binding (iC2Am-750) (Figure 6 A-C). Positive MSOT 
signal showed a good correlation with staining of apoptotic cells in tumor sections. 
 
A limitation of the current study was the very high levels of tumor cell death following 
treatment with MEDI3039.  However, we have shown previously that fluorescence 
imaging with C2Am labeled with AlexaFluor™-750 C5-maleimide was capable of 
detecting 5-FU-induced cell death in Colo205 tumors, where CC3 staining in tumor 
sections increased from 1 – 2% pre-treatment to 2 – 5% post treatment (25).  
Moreover, we have shown here that MSOT imaging with C2Am labeled with another 
NIR fluorophore was also capable of detecting 5-FU-induced tumor cell death.  
Tumor cell death in the clinic can range from less than 2% before treatment to 5%–
15% after treatment (45). 
 
Optoacoustic imaging with the C2Am probe described here has the potential to be 
used in the clinic to assess early treatment response in relatively superficial tumors, 
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such as in the breast (46), and in an endoscopic format (47), for assessing treatment 
response in tumors in the gastrointestinal tract. 
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Figure legends 
 
Figure 1.  Differential sensitivity of Colo205 and HT-29 cells to TRAILR2 
agonist-induced cell death.  A. Dose response of Colo205 and HT-29 cells to 
MEDI3039. Cell viabilities were measured by Trypan blue dye exclusion after 
incubating the cells with various drug concentrations (0-400 pM) for 22 h.  B. Dose 
response of Colo205-Dual cells, which express firefly luciferase, to MEDI3039.  Loss 
of ATP in these cells results in a loss of bioluminescence. Cells were incubated with 
various drug concentrations (0-100 pM) for 22 h. C. Representative bioluminescence 
images of Colo205-Dual cells at 22 h after incubation with the indicated drug 
concentration.  All experiments were performed in triplicate. 
 
Figure 2. Detection of TRAILR2 agonist-induced cell death using C2Am. (A) 
Confocal microscopy of drug-treated (upper panel) and untreated (lower panel) Colo-
Dual cells. Cell death was induced by treatment with 10 pM MEDI3039 for 5 h. The 
cells were co-incubated subsequently with C2Am-750 (green) and iC2Am-680 (red), 
washed and then imaged. Decreases in NADH autofluorescence (blue) and 
mStrawberry fluorescence (magenta) in treated cells indicated dead or dying cells. 
Merged images show the overlay of all the channels except the bright-field view. 
Scale bar = 5 µm. (B) Detection of drug-induced cell death in Colo205 and HT-29 
cells using flow cytometry. Cells were untreated or treated with 1 pM MEDI3039 for 
22 h and incubated subsequently with a cell necrosis marker, Sytox Green (upper 
panels), C2Am-750 (middle panels) or iC2Am-680 (lower panels). Low levels of 
NADH autofluorescence (x axis) and staining with Sytox Green were used to identify 
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dead cells. The numbers in the scatter plots represent the percentage of cells in the 
respective quadrants. 
 
Figure 3. Fluorescence imaging of TRAILR2 agonist-induced tumor cell death 
in vivo and ex vivo. (A) Nude mice bearing subcutaneous Colo205 tumors were 
treated with a single dose of 0.4 mg/kg MED3039.  Untreated mice were injected 
with solvent vehicle (PBS). After 16 h, the mice were injected with a mixture of 0.1 
µmole/kg C2Am-750 and 0.1 µmole/kg iC2Am-680 followed by whole body FLI 
measurements using an IVIS 200 camera at 30 min and 3 h post probe injection. 
The white arrows indicate the location of the tumor. (B) Histological validation of 
C2Am-750 labeling of MEDI3039-induced tumor cell death. MEDI3039-treated and 
untreated Colo205 tumors were excised at 3 h post probe injection. Paraffin 
embedded tumor sections were scanned for fluorescence (green: C2Am-750; blue: 
iC2Am-680; signal intensity bars are shown on the right hand side) followed by 
TUNEL staining and staining for cleaved capase-3 (CC3). (C) Quantitation of in vivo 
tumor fluorescence intensities at 3 h post injection of C2Am-750 and iC2Am-680. (D) 
Quantitation of fluorescence intensities in excised tumors from animals injected with 
C2Am-750 and iC2Am-680. The intensities have been normalized to tumor weight. * 
P<0.05, ** P<0.01, ***p<0.001. Scale bar = 3 mm. 
 
Figure 4. A single dose of TRAILR2 agonist produced a durable response in 
Colo-Dual tumors. (A) Colo-Dual cells (5 x 106) were implanted subcutaneously in 
nude mice at day 0.  Bioluminescence measurements were made on the resulting 
tumors starting from day 11 when, in the treated group (n=5), animals were injected 
with a single dose of 0.4mg/kg MEDI3039. Untreated animals (n=5) were injected 
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with drug vehicle (PBS). (B) Representative bioluminescence images of treated and 
untreated mice on day 11 and day 12. Imaging measurements were made just 
before injection of MEDI3039 on day 11 and then 24 h later on day 12.  
 
Figure 5. MSOT of treated and untreated mice injected with C2Am-750 or 
iC2Am-750. Nude mice bearing subcutaneous Colo205 tumors were either 
untreated (A) or treated with a single dose of 0.4 mg/kg MED3039 (B&C).  At 4 h 
after drug treatment MSOT measurements were made before (left panels) and at 3 h 
post injection of 0.2 µmole/kg of (i)C2Am-750 (right panels).  Signals from C2Am-
750/iC2Am-750, oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb) 
are shown in green, red and blue respectively.  The tumor is outlined by a white line 
in a - c. (D) Representative axial, coronal and sagittal views of a tumor before and 3 
h after injection of C2Am-750. (E) Representative 3D image of a tumor before and 3 
h after injection of C2Am-750. Scale bar = 3 mm. 
 
Figure 6. Serial measurements of C2Am-750 and iC2Am-750 retention in 
TRAILR2 agonist-treated Colo205 tumors. (A) Representative MSOT images of 
tumors (outlined), 4 h after drug treatment (0.4 mg/kg MED3039) and at the indicated 
times after injection of the probes. (B) Representative epi-fluorescence images 
acquired at the indicated times after probe injection. Signal was observed from the 
tumors (arrowed) and kidneys. (C) Quantification of probe uptake in 3D 
reconstructed volumes of interest (VOIs) in MSOT images acquired 24 h after probe 
injection. Signal-to-background ratios were calculated by dividing the mean pixel 
intensity (MPI) in a VOI within the tumor, where maximum signal was observed, by 
the MPI of an adjacent size-matched VOI. *** P<0.001 (n = 5) (D). Correlation of the 
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volume of tumor with bound C2Am-750 (VT), expressed as a percentage of the total 
tumor volume (T), with CC3 positive staining in non-consecutive tumor sections (five 
tumors; four sections per tumor). Scale bar = 3 mm. 
 
 






